Author Archives: adminoacido

  • 0

Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study.

Category : Epilepsia

Related Articles

Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study.

Brain Dev. 2018 Apr 16;:

Authors: Hausman-Kedem M, Menascu S, Kramer U

Abstract
The objective of this observational study was to evaluate the efficacy of medical cannabis for the treatment of refractory epilepsy. Fifty-seven patients (age 1-20 years) with epilepsy of various etiologies were treated with Cannabis oil extract (CBD/THC ratio of 20:1) for at least 3 months (Median follow up time-18 months). Forty-Six Patients were included in the efficacy analysis. Average CBD dose was11.4 mg/kg/d. Twenty-six patients (56%) had ≤50% reduction in mean monthly seizure frequency. There was no statistically significant difference in response rate among various epilepsy etiologies, and cannabis strain used. Younger age at treatment onset (<10 years) and higher CBD dose (>11 mg/kg/d) were associated with better response to treatment. Adverse reactions were reported in 46% of patients and were the main reason for treatment cessation. Our results suggest that adding CBD-enriched cannabis extract to the treatment regimen of patients with refractory epilepsy may result in a significant reduction in seizure frequency according to parental reports. Randomized controlled trials are necessary to assess its true efficacy.

PMID: 29674131 [PubMed – as supplied by publisher]

Powered by WPeMatico


  • -

The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Category : Antiinflamatorio

Related Articles

The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Psychoneuroendocrinology. 2017 Sep;83:58-64

Authors: Carol EE, Spencer RL, Mittal VA

Abstract
Recent studies have posited a relationship between cannabis use and the biological stress system, but this critical relationship has not been evaluated during the ultra high-risk (UHR) period immediately preceding the onset of psychotic disorders. Salivary cortisol samples were collected on 46 UHR and 29 control adolescents; these individuals were assessed for current cannabis use with a urine panel and self-report. UHR participants where separated into two groups: Current Cannabis Use (UHR-CU) and No Current Cannabis Use (UHR-NC). Healthy Control participants (HC) were free of cannabis use. Consistent with the literature, results indicate UHR individuals showed elevated cortisol levels when compared to HC participants. Further, we also observed that UHR-CU participants exhibited elevated levels when compared to both the non-using UHR and HC groups. Findings suggest that cannabis use may interact with underlying biological vulnerability associated with the hypothalamic-pituitary-adrenal (HPA) axis system.

PMID: 28595088 [PubMed – indexed for MEDLINE]

Powered by WPeMatico


  • -

Cannabis and Anti-Cancer Drugs: Societal Usage and Expected Pharmacological Interactions – A Review.

Category : Cancer

Related Articles

Cannabis and Anti-Cancer Drugs: Societal Usage and Expected Pharmacological Interactions – A Review.

Fundam Clin Pharmacol. 2018 Apr 16;:

Authors: Bouquié R, Deslandes G, Mazaré H, Cogné M, Mahé J, Grégoire M, Jolliet P

Abstract
Cannabis is a plant that has been used for centuries to relieve a wide range of symptoms. Since the 1960s, interest in medical research into this plant has grown steadily. Already very popular for recreational use, a growing number of consumers not accustomed to using cannabis for psychoactive purposes, have begun to use it as an alternative or complement to mainstream pharmaceutical medicines. The principal unsubstantiated or “social” uses of cannabis are based mainly on data that is at best controversial, but usually not scientifically proven. The aim of this review is to identify the scientific basis and reasons that lead patients with cancer to consume cannabis, and also to identify whether there is a risk of interaction between cannabis and anti-cancer medicines through drug transporters (P-glycoprotein and other ABC-superfamily members) Cytochromes P450 (3A, 1A, 2B, 2C 2D families…) and glucuronyl-transferases. This article is protected by copyright. All rights reserved.

PMID: 29660159 [PubMed – as supplied by publisher]

Powered by WPeMatico


  • -

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

Category : Dolor

Related Articles

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

J Neurol Sci. 2017 Aug 15;379:298-303

Authors: Santoro M, Mirabella M, De Fino C, Bianco A, Lucchini M, Losavio F, Sabino A, Nociti V

Abstract
Multiple sclerosis (MS) is a chronic demyelinating central nervous system (CNS) disease that involve oligodendrocyte loss and failure to remyelinate damaged brain areas causing a progressive neurological disability. Studies in MS mouse model suggest that cannabinoids ameliorate symptoms as spasticity, tremor and pain reducing inflammation via cannabinoid-mediated system. The aim of our study is to investigate the changes in cannabinoid type 1 (CNR1) and 2 (CNR2) receptors mRNA expression levels and promoter methylation in peripheral blood mononuclear cells (PBMCs) of MS secondary progressive (MSS-SP) patients treated with Sativex®. Our cohort included MSS-SP patients, that at the time of Sativex® treatment, are treated (n=7), not treated (n=11) or that had terminated interferon-β-1b (IFN-β-1b) therapy (n=12). By Methylation Sensitive High Resolution Melting (MS-HRM), we characterized the methylation profile of CNR1 and CNR2 promoter region, while the relative mRNA transcript levels of these two genes were evaluated in the same samples by Quantitative Real-Time PCR (qRT-PCR) analysis. We did not find different pattern of cytosine-phosphate-guanine (CpG) methylation in the CNR1/CNR2 promoter region of all MSS-SP patients treated with Sativex®. In addition, CNR1 and CNR2 expression did not significantly differ in MSS-SP patients not treated with IFN-β-1b vs. them that have suspended, while in MSS-SP patients treated with IFN-β-1b during Sativex® therapy we found a specific decrease of the CNR2 expression levels. These results suggest that the different expression of cannabinoid receptors by Sativex® treatment in leukocytes might be regulated through a molecular mechanism that involve interferon modulation.

PMID: 28716266 [PubMed – indexed for MEDLINE]

Powered by WPeMatico


  • -

[Cannabinoid therapy in practice].

Category : Cancer

Related Articles

[Cannabinoid therapy in practice].

Urologe A. 2018 Apr 12;:

Authors: Rasche T, Emmert D, Stieber C, Mücke M, Conrad R

Abstract
BACKGROUND: In recent years, the media and scientists have shown increased interest in cannabis-based drugs.
OBJECTIVES: Background information about cannabis-based drugs and their mechanism of action as well as discussion of possible applications as supportive therapy or in palliative medicine, respectively, are presented.
MATERIALS AND METHODS: The recent literature was examined and evaluated.
RESULTS: In many medical fields, we do not have sufficient evidence for the efficacy of cannabinoids. In German pharmaceutical legislation, the use of nabiximols for the treatment of intermediate to severe, therapy-resistant spasticity in multiple sclerosis is the only approved indication for cannabis-based drugs. Furthermore, in view of the current evidence cannabinoids, combined with established treatments and as part of an individual therapeutic attempt, can be used for neuropathic pain, cancer-associated pain and human immunodeficiency virus (HIV)-related cachexia.
CONCLUSIONS: In most cases, today’s assessment of cannabinoids relies on studies that are classified as low evidence. Therefore, further studies which involve more participants and evaluate long-term effects are needed.

PMID: 29651709 [PubMed – as supplied by publisher]

Powered by WPeMatico


  • -

Drug Memories: CBD and Addiction

Category : Noticias

the importance of forgetting in mental health should not be underestimated

Marijuana smokers have been stereotypically mocked for short-term memory loss, and there is genuine concern about memory impairment due to cannabis consumption, particularly among seniors who are considering cannabis as a therapeutic option.

But the importance of forgetting in mental health should not be underestimated.

Powered by WPeMatico


  • 0

Reefer to the Rescue: The Dope on Cannabidiol as a Multi-Symptom Panacea for Dravet Syndrome.

Category : Epilepsia

Reefer to the Rescue: The Dope on Cannabidiol as a Multi-Symptom Panacea for Dravet Syndrome.

Epilepsy Curr. 2018 Mar-Apr;18(2):118-120

Authors: Gupta A, Santhakumar V

PMID: 29643753 [PubMed]

Powered by WPeMatico


  • -

CBD and the Psychedelic Receptor

Category : Noticias

In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1  Serotonin is a complex molecule in the brain and the periphery with a vast and intricate receptor system classified into seven ma

Powered by WPeMatico


  • -

  • -

Cannabis and Humulus: A Family Reunion

Category : Noticias

Once upon a time, cannabis and humulus (hops) were the same plant.

About 27 million years ago, cannabis and hops diverged from their common ancestor and evolved as separate botanical species.

Today, cannabis and humulus are identified as distinct species within the same plant family Cannabaceae. One can see a family resemblance in the jagged-edged leaves emblematic of both plants.

Powered by WPeMatico


Translate »